Trial results from a study investigating user satisfaction with Rimegepant compared to triptans for acute treatment of Migraine were posted on ClinicalTrials.gov on 2025-08-11, involving a total of 1,536 participants.
Background
Migraine is a debilitating neurological condition characterized by severe headaches often accompanied by other symptoms such as throbbing pain, sensitivity to light and sound, and nausea. Effective acute treatments are crucial for managing migraine attacks and improving patients' quality of life. Triptans have long been a standard acute treatment, but newer options like rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, have emerged. Understanding patient satisfaction with these different acute treatments is important for guiding clinical decisions and personalizing care, especially given the diverse needs of individuals managing migraine.
Trial design
This completed study was a retrospective analysis collecting information from US users of the Migraine Buddy app between October 20, 2023, and May 20, 2024. The study enrolled 1,536 participants with Migraine who used either Nurtec (rimegepant) and/or triptans as an acute treatment, with or without background preventive treatment (anti-CGRP, Botox, or oral migraine preventive medications). The aim was to learn about user satisfaction with Nurtec or triptans, comparing the level of satisfaction between the two treatment types based on survey responses.
Key results
The trial results reported participant counts classified by their responses regarding satisfaction with pain intensity and attack duration. The specific categories for these responses were not detailed in the posted results.
- For the outcome 'Number of Participants Classified as Per Responses for Satisfaction of Pain Intensity':
- Participants in the Rimegepant group reported counts of 539, 130, and 39.
- Participants in the Triptans group reported counts of 625, 178, and 42.
- For the outcome 'Number of Participants Classified as Per Responses for Satisfaction With of Attack Duration':
- Participants in the Rimegepant group reported counts of 524, 145, and 39.
- Participants in the Triptans group reported counts of 571, 222, and 52.
What this means
The posted results provide data on user-reported satisfaction for acute migraine treatments, specifically Rimegepant and triptans, among a large cohort of Migraine Buddy app users. While the specific satisfaction categories corresponding to the participant counts are not detailed, the data offers insights into how users perceive these treatments in terms of pain intensity and attack duration. Clinicians and patients can consider these real-world satisfaction profiles when evaluating acute migraine treatment options, contributing to a more informed discussion about treatment effectiveness from a patient perspective.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06532357, titled "A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.", were posted on 2025-08-11 on clinicaltrials.gov.